Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.34
HZNP's Cash to Debt is ranked lower than
82% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.45 vs. HZNP: 0.34 )
Ranked among companies with meaningful Cash to Debt only.
HZNP' s Cash to Debt Range Over the Past 10 Years
Min: 0.07  Med: 0.92 Max: N/A
Current: 0.34
Equity to Asset 0.40
HZNP's Equity to Asset is ranked lower than
80% of the 707 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. HZNP: 0.40 )
Ranked among companies with meaningful Equity to Asset only.
HZNP' s Equity to Asset Range Over the Past 10 Years
Min: -0.77  Med: 0.45 Max: 0.7
Current: 0.4
-0.77
0.7
Interest Coverage 0.30
HZNP's Interest Coverage is ranked lower than
97% of the 467 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.06 vs. HZNP: 0.30 )
Ranked among companies with meaningful Interest Coverage only.
HZNP' s Interest Coverage Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0
Current: 0.3
F-Score: 5
Z-Score: 0.71
M-Score: -1.37
WACC vs ROIC
13.97%
-5.88%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 2.76
HZNP's Operating margin (%) is ranked lower than
66% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.72 vs. HZNP: 2.76 )
Ranked among companies with meaningful Operating margin (%) only.
HZNP' s Operating margin (%) Range Over the Past 10 Years
Min: -1841.5  Med: -401.76 Max: -2.86
Current: 2.76
-1841.5
-2.86
Net-margin (%) 1.61
HZNP's Net-margin (%) is ranked lower than
68% of the 716 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.15 vs. HZNP: 1.61 )
Ranked among companies with meaningful Net-margin (%) only.
HZNP' s Net-margin (%) Range Over the Past 10 Years
Min: -1635.12  Med: -447.20 Max: -88.77
Current: 1.61
-1635.12
-88.77
ROE (%) 1.18
HZNP's ROE (%) is ranked lower than
68% of the 744 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.16 vs. HZNP: 1.18 )
Ranked among companies with meaningful ROE (%) only.
HZNP' s ROE (%) Range Over the Past 10 Years
Min: -523.78  Med: -115.60 Max: -57.66
Current: 1.18
-523.78
-57.66
ROA (%) 0.50
HZNP's ROA (%) is ranked lower than
67% of the 769 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.76 vs. HZNP: 0.50 )
Ranked among companies with meaningful ROA (%) only.
HZNP' s ROA (%) Range Over the Past 10 Years
Min: -186.55  Med: -66.73 Max: -31.86
Current: 0.5
-186.55
-31.86
ROC (Joel Greenblatt) (%) 88.89
HZNP's ROC (Joel Greenblatt) (%) is ranked higher than
92% of the 762 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.16 vs. HZNP: 88.89 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
HZNP' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -7948.82  Med: -2263.21 Max: -154.09
Current: 88.89
-7948.82
-154.09
Revenue Growth (3Y)(%) 66.50
HZNP's Revenue Growth (3Y)(%) is ranked higher than
96% of the 602 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. HZNP: 66.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
HZNP' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -7.25 Max: 66.5
Current: 66.5
0
66.5
EPS Growth (3Y)(%) -37.00
HZNP's EPS Growth (3Y)(%) is ranked lower than
90% of the 503 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.70 vs. HZNP: -37.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
HZNP' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -56.90 Max: -37
Current: -37
» HZNP's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-07)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

HZNP Guru Trades in Q2 2015

RS Investment Management 964,160 sh (New)
Steve Mandel 3,204,972 sh (New)
Jim Simons 1,216,800 sh (+238.54%)
Paul Tudor Jones 137,400 sh (+201.92%)
Steven Cohen 325,000 sh (+38.95%)
» More
Q3 2015

HZNP Guru Trades in Q3 2015

Ron Baron 31,999 sh (New)
Steve Mandel 15,600,988 sh (+386.77%)
RS Investment Management 1,383,550 sh (+43.50%)
Jim Simons 465,912 sh (-61.71%)
Paul Tudor Jones 12,038 sh (-91.24%)
Steven Cohen 900 sh (-99.72%)
» More
Q4 2015

HZNP Guru Trades in Q4 2015

Ken Heebner 205,000 sh (New)
Julian Robertson 823,577 sh (New)
Joel Greenblatt 2,075,017 sh (New)
Paul Tudor Jones 48,570 sh (+303.47%)
RS Investment Management 2,210,448 sh (+59.77%)
Steve Mandel 15,600,988 sh (unchged)
Ron Baron Sold Out
Steven Cohen Sold Out
Jim Simons 302,400 sh (-35.10%)
» More
Q1 2016

HZNP Guru Trades in Q1 2016

Steven Cohen 1,019,400 sh (New)
Ken Heebner 330,000 sh (+60.98%)
Paul Tudor Jones 72,983 sh (+50.26%)
Julian Robertson 868,477 sh (+5.45%)
Jim Simons Sold Out
Steve Mandel 13,997,232 sh (-10.28%)
RS Investment Management 1,453,024 sh (-34.27%)
Joel Greenblatt 1,053,933 sh (-49.21%)
» More
» Details

Insider Trades

Latest Guru Trades with HZNP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:XTER:SAZ, NAS:ENDP, TSE:4516, SZSE:000028, SZSE:000999, SZSE:000623 » details
Traded in other countries:HPR.Germany,
Horizon Pharma PLC is a specialty pharmaceutical company. The Company's product portfolio consists of ACTIMMUNE, DUEXIS, PENNSAID 2% and RAYOS/LODOTRA, which addresses the unmet therapeutic needs in arthritis, pain, inflammatory and/or orphan diseases.

Horizon Pharma PLC was incorporated on March 23, 2010. The Company is a specialty pharmaceutical company commercializing DUEXIS, VIMOVO and RAYOS/LODOTRA, each of which targets unmet therapeutic needs in arthritis, pain and inflammatory diseases. DUEXIS is a proprietary single tablet formulation containing a fixed-dose combination of ibuprofen, one of the widely prescribed NSAIDs, and famotidine, a well-established GI agent used to treat dyspepsia, gastroesophageal reflux disease, or GERD, and active ulcers, in one pill. Ibuprofen has proven anti-inflammatory and analgesic properties and famotidine reduces the stomach acid secretion that can cause upper GI ulcers. VIMOVO is a proprietary fixed-dose multi-layer delayed-release tablet combining an enteric-coated naproxen, an NSAID, core and an immediate-release esomeprazole, a PPI, layer surrounding the core. Naproxen has proven anti-inflammatory and analgesic properties and esomeprazole reduces the stomach acid secretions that can cause upper GI ulcers. RAYOS, known as LODOTRA outside the United States, is a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe, active RA in adults particularly when accompanied by morning stiffness. DUEXIS and VIMOVO compete with other branded NSAIDs, including Celebrex, marketed by Pfizer Inc. RAYOS/LODOTRA competes in Europe and in the United States with a number of products on the market to treat RA, including corticosteroids, such as prednisone, traditional DMARDs, such as methotrexate and biologic agents, such as HUMIRA and Enbrel.

Top Ranked Articles about Horizon Pharma PLC

Mandel’s Lone Pine Takes Stake in Growing Horizon Pharma
Steven Mandel’s hedge fund, Lone Pine Capital, on July 27 initiated a position in Horizon Pharma Plc (NASDAQ:HZNP), according to GuruFocus Real Time Picks. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 184.45
HZNP's P/E(ttm) is ranked lower than
94% of the 558 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.44 vs. HZNP: 184.45 )
Ranked among companies with meaningful P/E(ttm) only.
HZNP' s P/E(ttm) Range Over the Past 10 Years
Min: 81.83  Med: 106.39 Max: 213.64
Current: 184.45
81.83
213.64
Forward P/E 4.56
HZNP's Forward P/E is ranked higher than
96% of the 90 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.95 vs. HZNP: 4.56 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 184.45
HZNP's PE(NRI) is ranked lower than
94% of the 549 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.81 vs. HZNP: 184.45 )
Ranked among companies with meaningful PE(NRI) only.
HZNP' s PE(NRI) Range Over the Past 10 Years
Min: 81.05  Med: 105.38 Max: 208.89
Current: 184.45
81.05
208.89
Price/Owner Earnings (ttm) 13.23
HZNP's Price/Owner Earnings (ttm) is ranked higher than
84% of the 265 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.19 vs. HZNP: 13.23 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
HZNP' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 10.71  Med: 33.31 Max: 43.31
Current: 13.23
10.71
43.31
P/B 2.03
HZNP's P/B is ranked higher than
66% of the 762 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.80 vs. HZNP: 2.03 )
Ranked among companies with meaningful P/B only.
HZNP' s P/B Range Over the Past 10 Years
Min: 0.8  Med: 2.31 Max: 14.94
Current: 2.03
0.8
14.94
P/S 3.18
HZNP's P/S is ranked lower than
52% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.76 vs. HZNP: 3.18 )
Ranked among companies with meaningful P/S only.
HZNP' s P/S Range Over the Past 10 Years
Min: 1.34  Med: 4.08 Max: 12.65
Current: 3.18
1.34
12.65
PFCF 8.62
HZNP's PFCF is ranked higher than
87% of the 199 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 26.71 vs. HZNP: 8.62 )
Ranked among companies with meaningful PFCF only.
HZNP' s PFCF Range Over the Past 10 Years
Min: 7.01  Med: 50.44 Max: 499.62
Current: 8.62
7.01
499.62
POCF 8.31
HZNP's POCF is ranked higher than
83% of the 265 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.71 vs. HZNP: 8.31 )
Ranked among companies with meaningful POCF only.
HZNP' s POCF Range Over the Past 10 Years
Min: 6.73  Med: 44.17 Max: 223.97
Current: 8.31
6.73
223.97
EV-to-EBIT 145.96
HZNP's EV-to-EBIT is ranked lower than
95% of the 537 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.64 vs. HZNP: 145.96 )
Ranked among companies with meaningful EV-to-EBIT only.
HZNP' s EV-to-EBIT Range Over the Past 10 Years
Min: -775.4  Med: -1.80 Max: 219.8
Current: 145.96
-775.4
219.8
EV-to-EBITDA 17.63
HZNP's EV-to-EBITDA is ranked higher than
52% of the 569 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.81 vs. HZNP: 17.63 )
Ranked among companies with meaningful EV-to-EBITDA only.
HZNP' s EV-to-EBITDA Range Over the Past 10 Years
Min: -608  Med: -0.50 Max: 518
Current: 17.63
-608
518
Current Ratio 1.98
HZNP's Current Ratio is ranked lower than
60% of the 662 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. HZNP: 1.98 )
Ranked among companies with meaningful Current Ratio only.
HZNP' s Current Ratio Range Over the Past 10 Years
Min: 0.16  Med: 1.99 Max: 4.39
Current: 1.98
0.16
4.39
Quick Ratio 1.57
HZNP's Quick Ratio is ranked lower than
60% of the 662 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.87 vs. HZNP: 1.57 )
Ranked among companies with meaningful Quick Ratio only.
HZNP' s Quick Ratio Range Over the Past 10 Years
Min: 0.16  Med: 1.80 Max: 4.27
Current: 1.57
0.16
4.27
Days Inventory 69.20
HZNP's Days Inventory is ranked higher than
76% of the 668 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.30 vs. HZNP: 69.20 )
Ranked among companies with meaningful Days Inventory only.
HZNP' s Days Inventory Range Over the Past 10 Years
Min: 13.1  Med: 62.31 Max: 190.54
Current: 69.2
13.1
190.54
Days Sales Outstanding 124.86
HZNP's Days Sales Outstanding is ranked lower than
78% of the 620 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.15 vs. HZNP: 124.86 )
Ranked among companies with meaningful Days Sales Outstanding only.
HZNP' s Days Sales Outstanding Range Over the Past 10 Years
Min: 64.38  Med: 88.33 Max: 124.99
Current: 124.86
64.38
124.99
Days Payable 94.93
HZNP's Days Payable is ranked higher than
66% of the 589 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 71.47 vs. HZNP: 94.93 )
Ranked among companies with meaningful Days Payable only.
HZNP' s Days Payable Range Over the Past 10 Years
Min: 97.38  Med: 215.25 Max: 410.36
Current: 94.93
97.38
410.36

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 2.31
HZNP's Price/Projected FCF is ranked higher than
56% of the 311 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.53 vs. HZNP: 2.31 )
Ranked among companies with meaningful Price/Projected FCF only.
HZNP' s Price/Projected FCF Range Over the Past 10 Years
Min: 2.3  Med: 8.73 Max: 29.51
Current: 2.31
2.3
29.51
Price/Median PS Value 0.77
HZNP's Price/Median PS Value is ranked higher than
83% of the 680 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.09 vs. HZNP: 0.77 )
Ranked among companies with meaningful Price/Median PS Value only.
HZNP' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.39  Med: 1.06 Max: 2.76
Current: 0.77
0.39
2.76
Earnings Yield (Greenblatt) (%) 0.68
HZNP's Earnings Yield (Greenblatt) (%) is ranked lower than
66% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. HZNP: 0.68 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
HZNP' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.5  Med: 0.80 Max: 1.9
Current: 0.68
0.5
1.9

More Statistics

Revenue (TTM) (Mil) $848.6
EPS (TTM) $ 0.09
Beta1.79
Short Percentage of Float11.56%
52-Week Range $12.86 - 39.49
Shares Outstanding (Mil)160.36

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 1,006 1,167 1,307
EPS ($) 2.23 3.64 3.25
EPS without NRI ($) 2.23 3.64 3.25
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for HZNP

Headlines

Articles On GuruFocus.com
Julian Robertson Buys 8 New Stakes in 4th Quarter Mar 09 2016 
Sheets Smith Wealth Management Buys Companies With no Debts Sep 01 2015 
Horizon Pharma Leads Stock Returns in Health Care Industry Aug 24 2015 
Mandel’s Lone Pine Takes Stake in Growing Horizon Pharma Jul 28 2015 
M&A’s Driving The Stock Indexes Ahead Apr 06 2015 
Biotech Effectiveness: Horizon Pharma, Zafgen, XOMA Corp Mar 09 2015 

More From Other Websites
Horizon Pharma Plc breached its 50 day moving average in a Bullish Manner : HZNP-US : May 26, 2016 May 26 2016
Biotech Stock Roundup: XenoPort Soars on Acquisition Deal, AbbVie Crohn's Disease Drug Fares Well May 25 2016
Loving 'unloved' stocks: Pro May 23 2016
Horizon (HZNP) to Buy Global Rights to Actimmune, Stock Down May 20 2016
Horizon Pharma plc to Acquire Worldwide Rights to Interferon Gamma-1b From Boehringer Ingelheim... May 19 2016
HORIZON PHARMA PLC Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 19 2016
Horizon Pharma plc to Acquire Worldwide Rights to Interferon Gamma-1b From Boehringer Ingelheim... May 19 2016
Horizon Pharma plc to Participate in UBS Global Healthcare Conference May 18 2016
Horizon Pharma plc to Participate in UBS Global Healthcare Conference May 18 2016
HORIZON PHARMA PLC Financials May 18 2016
ETF’s with exposure to Horizon Pharma Plc : May 16, 2016 May 16 2016
Horizon Pharma Plc :HZNP-US: Earnings Analysis: Q1, 2016 By the Numbers May 12 2016
Bulls bet on rebound in Horizon Pharma May 12 2016
A Move Lower Is on the Horizon (Pharma) May 12 2016
Horizon Pharma plc Announces That Marilyn Vetter Honored as a 2016 Healthcare Businesswomen's... May 12 2016
Horizon Pharma plc Announces That Marilyn Vetter Honored as a 2016 Healthcare Businesswomen's... May 12 2016
Horizon Pharma plc Announces Settlement of PENNSAID(R) (diclofenac sodium topical solution) 2% w/w... May 12 2016
Horizon Pharma plc Announces Settlement of PENNSAID(R) (diclofenac sodium topical solution) 2% w/w... May 12 2016
Nuvo Pharmaceuticals™ Announces 2016 First Quarter Results May 11 2016
IBB Mid-Cap Stocks: Horizon Pharma Soars on Better Earnings May 11 2016
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of Additional Notice of... May 11 2016
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of Additional Notice of... May 11 2016
Horizon Pharma Plc: Strong price momentum but will it sustain? May 10 2016
Horizon (HZNP) Stock Up Despite Earnings & Revenue Miss May 10 2016
Teva Reports Better-Than-Expected Q1 As Revenue from Branded Biz Beats Estimates May 09 2016
Horizon Pharma reports 1Q loss May 09 2016
Horizon Pharma plc Announces First-Quarter 2016 Financial Results May 09 2016
Horizon Pharma plc Completes Target Enrollment of 90 Patients for Phase 3 Trial of ACTIMMUNE(R)... May 05 2016
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of Three Additional... May 04 2016
Horizon Pharma plc to Present at Two Investor Conferences in May May 03 2016
Horizon Pharma plc Announces Settlement of PENNSAID(R) (diclofenac sodium topical solution) 2% w/w... Apr 25 2016
Horizon Pharma plc to Host First-Quarter 2016 Conference Call and Webcast on May 9, 2016 Apr 18 2016
Horizon Pharma plc Named to Crain's Chicago Business First Ever 2016 "Best Places To Work for Women... Apr 04 2016
Horizon Pharma plc Receives Health Canada Approval for RAVICTI(R) (glycerol phenylbutyrate) Oral... Mar 21 2016
Robbins Arroyo LLP: Horizon Pharma plc (HZNP) Misled Shareholders According to a Recently Filed... Mar 14 2016
Horizon Pharma misses 4Q profit forecasts Feb 29 2016
Horizon Pharma plc to Host Fourth Quarter 2015 Conference Call and Webcast on February 29, 2016 Jan 29 2016
Horizon Pharma plc to Participate in Three Investor Conferences in February Jan 28 2016
Horizon Pharma plc Completes Acquisition of Crealta Holdings LLC Jan 14 2016
Horizon Pharma increases full-year sales forecast Jan 12 2016
Horizon Pharma plc Raises Full-Year 2016 Net Sales and Adjusted EBITDA Guidance Based on Expected... Jan 12 2016
Horizon Pharma plc to Present at the 34th Annual J.P. Morgan Healthcare Conference Jan 06 2016
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice... Jan 04 2016
Horizon Pharma plc to Present at the 34th Annual J.P. Morgan Healthcare Conference Dec 17 2015
Horizon Pharma buying Crealta for $510 million Dec 11 2015
Horizon drops hostile bid for Depomed after judge's ruling Nov 19 2015
Express Scripts sues Horizon, fight over prescriptions grows Nov 11 2015
A farewell letter from Philidor, perhaps Nov 11 2015
Horizon Pharma posts 3Q profit Nov 06 2015
Analysis - Valeant plunge spotlights cracks in specialty pharma's M&A facade Oct 21 2015
Horizon passes regulatory hurdle in pursuit of Depomed Oct 09 2015
Depomed rejects Horizon's latest takeover offer Sep 14 2015
Horizon takes hostile Depomed bid directly to shareholders Sep 08 2015
Horizon pushes hostile Depomed bid with shareholder offer Sep 08 2015
Horizon Pharma beats 2Q profit forecasts Aug 07 2015
Horizon asks for Depomed vote, files lawsuit in hostile bid Aug 03 2015
Ahead of the Bell: Depomed rejects Horizon offer Jul 30 2015
Horizon Pharma raises bid for Depomed to $33 per share Jul 21 2015
Horizon Pharma raises offer for Depomed Jul 21 2015
Depomed puts 'poison pill' plan in place Jul 13 2015
US stocks head higher as Greece debt talks proceed Jul 07 2015
US STOCKS-Wall St lower on China concerns; Greece watched Jul 07 2015
US HY CLOSE-High-yield week tally goes over US$10bn Apr 24 2015
US HY CLOSE-Three high-yield issuers raise US$1.815bn Apr 23 2015
US STOCKS-Wall St rebounds from recent losses; deals help Mar 30 2015
GLOBAL MARKETS-Stocks gain on merger activity; dollar rises Mar 30 2015
US STOCKS-Wall St bounces back from recent losses; deals help Mar 30 2015
GLOBAL MARKETS-Stocks gain on merger activity, dollar rises Mar 30 2015
US STOCKS-Wall St higher as biotechs rally on M&A deals Mar 30 2015
Ireland's Horizon to buy U.S. drugmaker Hyperion for $1.1 bln Mar 30 2015
US STOCKS-Wall St higher as biotechs rally on M&A deals Mar 30 2015
US STOCKS-Futures higher, but crude oil weakens Mar 30 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)